ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress

Martin H. Neumann(Bayer (Germany)), Sebastian Bender(Bayer (Germany)), Thomas Krahn(Bayer (Germany)), Thomas Schlange(Bayer (Germany))
Computational and Structural Biotechnology Journal
January 1, 2018
10.1016/j.csbj.2018.05.002
Cited by 204Open Access
Full Text

Abstract

We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview of corresponding technologies is given.

Related Papers

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli, G. Thomas Budd, Matthew J. Ellis et al.|New England Journal of Medicine|2004|4.6k
Metastasis: from dissemination to organ-specific colonization
Don X. Nguyen, Paula D. Bos, Joan Massagué|Nature reviews. Cancer|2009|2.6k
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman, Scott V. Bratman, Jacqueline To et al.|Nature Medicine|2014|2.2k
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza, Sarah‐Jane Dawson, Dana W.Y. Tsui et al.|Nature|2013|1.6k
Tumour heterogeneity in the clinic
Philippe L. Bédard, Aaron R. Hansen, Mark J. Ratain et al.|Nature|2013|1.2k